Pregled bibliografske jedinice broj: 667014
The expression of glial fibrillary acidic protein in the brain of streptozotocin rat model of sporadic Alzheimer’s disease
The expression of glial fibrillary acidic protein in the brain of streptozotocin rat model of sporadic Alzheimer’s disease // Clinical Neuropathology 31(4) / Ironside, James (ur.).
Edinburgh: British Neuropathological Society, 2012. str. 290-290 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 667014 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
The expression of glial fibrillary acidic protein in the brain of streptozotocin rat model of sporadic Alzheimer’s disease
Autori
Knezović, Ana ; Knapić, Marina ; Šimić, Goran ; Šalković-Petrišić, Melita
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Clinical Neuropathology 31(4)
/ Ironside, James - Edinburgh : British Neuropathological Society, 2012, 290-290
Skup
10th European Congress of Neuropathology
Mjesto i datum
Edinburgh, Ujedinjeno Kraljevstvo, 06.06.2012. - 09.06.2012
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
astrocyte; streptozotocin; Alzheimer's disease
Sažetak
Introduction: Central administration of streptozotocin (STZ-icv) induces Alzheimer-like behavioural and neurochemical changes in rat due to the STZ-icv rat has been recently proposed as its animal model. Activated microglia and astrocytes were found in the cortex and hippocampus up to 8 weeks after the STZ-icv administration. We have investigated the STZ-icv dose-dependency of astrogliosis development 1 week and 3 months after the STZ-icv treatment. Methods: Adult male Wistar rats were administered STZ (0.1, 1 and 3 mg/kg dose) or vehicle (controls) icv injections and sacrificed 1 week and 3 months afterwards. Paraffin-embedded brain sections of pre-mortally fixative perfused animals were analysed by immunohistochemistry of glial fibrillary acidic protein (GFAP), a marker of astrogliosis. Results: Highly increased GFAP expression both in number and cell size was found focused in the cortex, around the cannula penetration area, and in hippocampus 1 week after the STZ-icv administration with all STZ-icv doses as well in the control animals. Three months after the treatment, distribution and cell size were found normalized in all treated groups as well as their number, with the exception of slightly increase with the 0.3 mg/kg STZ-icv dose only. Conclusions: Preliminary results demonstrate that STZ-icv rat model develops acute, non-specific anti-inflammatory response, regardless the STZ-icv dose, which tends to normalize three months after the treatment. Acknowledgement: Supported by the Unity Through Knowledge Fund (UKF 64-10) and MZOS.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
POVEZANOST RADA
Projekti:
108-1080003-0020 - Mozak, eksperimentalni i cerebralni dijabetes i kognitivni i drugi poremećaji (Šalković-Petrišić, Melita, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb